Portfolio News
- February 23, 2010 Intellikine Appoints William Rohn to Its Board of Directors
- February 23, 2010 Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
- February 08, 2010 Anthera Pharmaceuticals Announces Agreement with the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
- February 08, 2010 InteKrin Therapeutics' Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
- January 27, 2010 Movetis launches Resolor® in Germany
- January 21, 2010 Laszlo Systems Secures $3M Financing from MMV Financial
- January 13, 2010 - BioWorld TodayStructural Study of PI3 Kinase Suggests Targeting Strategies
- January 12, 2010 3D Structure of Key Drug Target Sheds Light on How to Design Better Drugs
- January 11, 2010 KaloBios Partners with Sanofi Pasteur on Novel Prevention and Treatment for Pseudomonas Aeruginosa
- January 11, 2010 InterMune Provides Program Update and 2010 Milestones for RG7227 (ITMN-191)
- January 11, 2010 Amarin Corporation Announces First Patients Enrolled in Two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovascular Disease
- January 07, 2010 Threshold Pharmaceuticals Announces Preclinical Multiple Myeloma Data
- January 05, 2010 - Xconomy San DiegoIntellikine Tests First Cancer Drug in Humans, Just Two Years After Opening Labs
- December 21, 2009 Durata Therapeutics Launches, Buys Virucon Pharma
- December 21, 2009 Movetis raises a total of €97.75m via an additional €12.75 million Over-allotment Option